Background: Pancreatic cancer (PC) is one of the most lethal malignant tumors with no valid biomarkers for early diagnosis. We evaluated the value of PD-1, PD-L1, PD-L2, CD28, B7-1, and B7-H5 for diagnosing PC.
Methods: We measured serum soluble PD-1, PD-L1, PD-L2, CD28, B7-1, and B7-H5, and serum carbohydrate antigen (CA)19-9 levels in 87 patients with PC, 27 patients with benign pancreatic disease, and 20 healthy volunteers. We evaluated the diagnostic value of CA19-9, PD-1, PD-L1, PD-L2, CD28, B7-1, B7-H5.
Results: Patients with PC had significantly higher serum CA19-9, PD-L1, PD-L2, and B7-H5. Combined detection (CA19-9 + PD-L1 + PD-L2 + B7-H5) had much higher sensitivity than single CA19-9 detection.
Conclusions: Serum soluble PD-L1, PD-L2, and B7-H5 might be novel potential biomarkers for diagnosing PC; their combination with serum CA19-9 might improve diagnostic sensitivity and specificity.